Lupus

Exciting Updates in the World of Lupus: New Board Members, Cardiovascular Risks, and Treatment Breakthrough

New board members join Lupus Foundation of America, increased cardiovascular risks in SLE patients, and a promising treatment for Cutaneous Lupus. Read on for the latest updates!

In the realm of Lupus, exciting developments are taking place. The Lupus Foundation of America is proud to welcome Brian Antonsen and Theresa Juday as new additions to its board of directors, bringing fresh perspectives and expertise to further their mission. Studies have highlighted an increased cardiovascular risk in Korean patients with systemic lupus erythematosus (SLE), emphasizing the importance of managing this aspect of the disease. Additionally, a recent study focusing on adolescent patients with SLE showed promising results with anifrolumab (Saphnelo), demonstrating significant and sustained improvements in treating Cutaneous Lupus.

As the Lupus Foundation of America expands its leadership team, the spotlight shines on the critical issue of cardiovascular health in SLE patients. Understanding and addressing this elevated risk can significantly impact the quality of life for those living with Lupus. The breakthrough in utilizing anifrolumab to effectively treat Cutaneous Lupus opens up new possibilities for improved management and relief for patients facing this specific form of the disease.

In conclusion, the landscape of Lupus research and treatment is evolving rapidly, with advancements in board leadership, cardiovascular risk awareness, and treatment innovation. These developments pave the way for a brighter future for individuals battling Lupus, offering hope and progress in the quest for better care and outcomes.